Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neogen Corporation (NEOG) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Neogen’s operations in food safety, animal safety, and related markets, as well as its governance, compensation practices, and financial condition.
Neogen uses current reports on Form 8-K to disclose material events such as the appointment of a new President and Chief Executive Officer, changes in the Chief Financial Officer role, director retirements and appointments, and the results of shareholder votes at its annual meeting. Filings describe executive compensation arrangements, including base salary, annual bonus targets, long-term equity incentives, and performance share unit programs tied to metrics like revenue growth, adjusted EBITDA margin expansion, and cash flow conversion.
Investors can also review 8-K filings that furnish earnings press releases, which summarize quarterly and annual results, segment performance for Food Safety and Animal Safety, and non-GAAP measures such as adjusted EBITDA. These filings complement the company’s financial statements by providing narrative context and reconciliations.
On Stock Titan, NEOG filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain key elements of lengthy documents, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Users can quickly identify disclosures related to executive and director changes, incentive plans, shareholder meeting outcomes, and other governance matters.
This page is a resource for understanding how Neogen describes its strategy, risk factors, performance metrics, and capital structure in its own words through formal SEC filings, with tools to make complex regulatory content more accessible.
Neogen Corp (NEOG) insider activity: Douglas Edward Jones, the Chief Operating Officer and a director, reported transactions on 08/18/2025 where 14,294 restricted stock units vested and were settled into 14,294 shares at an implied price of $5.43 per share, increasing his beneficial ownership to 86,007 shares. The filing also shows a separate disposition of 4,160 shares at $5.43, leaving 81,847 shares after that sale. The Form 4 was signed by an attorney-in-fact on 08/20/2025. The filer notes each RSU is the economic equivalent of one common share and that the RSUs vested and were settled on 08/18/2025.
Neogen Corp (NEOG) Form 4 summary: Chief Financial Officer David H. Naemura reported vesting and settlement of 14,294 restricted stock units on 08/18/2025 at an indicated price of $5.43 per share, resulting in acquisition of 14,294 shares. The filing also shows a contemporaneous disposition of 5,947 shares at $5.43, leaving the reporting person with 69,781 shares after the transactions. The form was signed by an attorney-in-fact on 08/20/2025. This filing documents an insider equity vesting event and partial sale of shares.
Neogen Corp (NEOG) insider activity: Amy M. Rocklin, Chief Legal Officer, had 10,324 restricted stock units vest on 08/18/2025 and those RSUs were settled into 10,324 shares at $5.43 per share. On the same date she acquired 10,324 shares and sold 3,005 shares at $5.43, leaving her with 44,170 shares beneficially owned following the transactions.
Neogen Corp (NEOG) insider transaction: John Patrick Moylan, Chief Accounting Officer and director, reported that on 08/18/2025 1,985 restricted stock units vested and were settled for 1,985 shares of common stock at a per-share value of $5.43. To cover obligations, 593 shares were disposed of at the same price, leaving Mr. Moylan with 14,347 shares beneficially owned after the transactions. The Form 4 was filed on 08/20/2025 and signed by an attorney-in-fact.
David H. Naemura, identified as an officer (CFO) and director, reported insider purchases for NEOG on 08/15/2025. He acquired 230,203 shares of Neogen common stock at $5.43 per share, bringing his total beneficial ownership to 291,637 shares. The filing also reports derivative securities: 591,690 rights/options to buy common stock with a $5.43 exercise price, acquired 08/15/2025 and exercisable immediately, expiring 08/15/2035. The disclosure states the options vest in equal annual installments over the first three anniversaries and that performance stock units vest in full at the three-year anniversary. The form was signed by an attorney-in-fact on 08/19/2025.
Amy M. Rocklin, Chief Legal Officer of Neogen Corp (NEOG), reported equity awards and option grants that increase her direct ownership. She acquired 119,705 common shares at $5.43 per share, bringing her direct beneficial ownership to 156,556 shares. In addition, she received a derivative award giving the right to buy 307,680 shares at an exercise price of $5.43, exercisable through 08/15/2035.
The filing notes the option grants vest in equal annual installments over the first three anniversaries of the grant and that performance stock units vest in full at the three-year anniversary. All reported holdings are direct ownership.
Neogen Corp insider filing: John Patrick Moylan, identified as a director and Chief Accounting Officer, reported purchases on 08/15/2025. He acquired 18,416 shares of NEOG common stock at a price of $5.43 per share, bringing his total reported beneficial ownership to 31,371 shares. The filing also reports acquisition of derivative rights described as the right to buy 47,336 shares at a $5.43 exercise price, exercisable beginning 08/15/2025 and expiring 08/15/2035, with 47,336 underlying shares shown as beneficially owned following the transaction. The filing notes that options and restricted stock units vest in equal annual installments on each of the first three anniversary dates of the grants.
Nassif Mikheal, identified as CEO and a director of Neogen Corp (NEOG), reported multiple acquisitions on 08/15/2025. He acquired 184,162 shares of common stock and 414,365 shares of common stock at $5.43 per share, leaving 598,527 shares beneficially owned after the transactions. He also acquired derivative rights (options/RSU/PSU grants) exercisable into 1,065,042 and 473,352 shares with an exercise/conversion price of $5.43 and expiration/vesting noted as 08/15/2035. The filing includes vesting schedule notes: some options/RSUs vest over three years, others over four years, and PSUs vest in total at the three-year anniversary. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Nassif Mikheal, identified as Chief Executive Officer, submitted an initial Form 3 reporting his relationship to Neogen Corp (NEOG).
The filing states that no securities are beneficially owned by the reporting person. The form was filed by a single reporting person and bears a signature executed by an attorney‑in‑fact, Christopher Sefcheck.
Neogen Corporation reported changes to its Board of Directors. William T. Boehm, a director since 2011 who chairs the Audit Committee and serves on the Compensation & Talent Management Committee, has notified the company that he will retire from the Board when his term ends on October 23, 2025. This marks the planned departure of a long-serving director with key committee responsibilities.
The Board has appointed Avi Pelossof as a new Class II director, effective October 24, 2025. He will participate in Neogen’s standard non-employee director compensation program, as previously described in the company’s 2024 proxy statement. The filing highlights his more than 25 years of diagnostics experience, including leadership roles at Immucor Inc. and Alere Inc., where he oversaw a $750 million infectious disease portfolio and the launch of an FDA CLIA-waived point-of-care molecular test.